Figure 1.

In vitro activity against R-E leukemia. (A) 78 compounds showed an average of 28.1% inhibition of Kasumi-1 cell growth, while they on average caused 0.2% growth inhibition against Jurkat cells (p<0.0001). (B) Dose-response curves for treatment of Kasumi-1 cells with Dex-P (in blue), Bet (in red) and Hydrocortisone (in green) and those for treatment of Jurkat (in black) and MCF-7 (in brown) cells with Bet. (C) Treatment of primary cells from a t(8;21) AML patient with Bet and hydrocortisone-inhibited colony-forming ability (EC₅₀: ~50 nM and 500 nM). (D) Treatment with Bet and Dex-P potently inhibited the colony-forming ability of R-E or R-E9a transformed LICs (EC₅₀: ~8 nM and 2 nM). (E) Treatment with Bet and Dex-P did not significantly affect colony-forming ability of murine hematopoietic stem/progenitor cells (HSPC).